PATENT CLAIM ANALYSIS

Application Number: 16131945
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "050000"]

Abstract:
Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.

Claim (Index 4):
The method of  claim 1 , wherein the amount of nintedanib administered is effective to extend the duration of lower intraocular pressure (IOP), increase either the absolute success rate or the qualified success rate for at least 10 days following glaucoma surgery; or wherein the amount of nintedanib administered is effective to prolong bleb survival.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.11429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15375820', '15474620', '15991382', '15991698', '13800912']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7791581144506123
- 35 USC 102 Novelty (BERT): 0.5210325362541409
- Combined Prediction Score: 0.7533455566309653
- Mean Citation Score: 278.90584
- Max Citation Score: 296.6952
- Similarity Product: 185.48995831604003

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test